Suchergebnisse - "Yokoyama, Keitaro"

PubPharm (37)

1

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism : results of a post-marketing surveillance in Japan

enthalten in: Clinical and experimental nephrology | 2021

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +5

2

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism

enthalten in: Nephrology (Carlton, Vic.) | 2020

von Shigematsu, T. | Fukagawa, M. | Yokoyama, K. | +4

3

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level : an analysis from the MBD-5D study

enthalten in: Clinical and experimental nephrology | 2020

von Asada, S. | Yokoyama, K. | Miyakoshi, C. | +8

4

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study

enthalten in: Clinical and experimental nephrology | 2020

von Asada, S. | Yokoyama, K. | Miyakoshi, C. | +8

5

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study

enthalten in: Clinical and experimental nephrology | 2020

von Asada, S. | Yokoyama, K. | Miyakoshi, C. | +8

6

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study

enthalten in: Clinical and experimental nephrology | 2020

von Asada, S. | Yokoyama, K. | Miyakoshi, C. | +8

7

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis

enthalten in: Scientific reports | 2019

von Yokoyama, K. | Shimazaki, R. | Fukagawa, M. | +17

8

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

enthalten in: Clinical and experimental nephrology | 2018

von Shigematsu, T. | Fukagawa, M. | Yokoyama, K. | +46

9

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

enthalten in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2017

von Fukagawa, M. | Yokoyama, K. | Shigematsu, T. | +6

10

A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients 

enthalten in: Clinical nephrology | 2017

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +4